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Abstract Congestive heart failure developing after acute
myocardial infarction (AMI) is a major cause of morbidity
and mortality. Clinical trials of cell-based therapy after
AMI evidenced only a moderate beneﬁt. We could show
previously that suspensions of apoptotic peripheral blood
mononuclear cells (PBMC) are able to reduce myocardial
damage in a rat model of AMI. Here we experimentally
examined the biochemical mechanisms involved in pre-
venting ventricular remodelling and preserving cardiac
function after AMI. Cell suspensions of apoptotic cells
were injected intravenously or intramyocardially after
experimental AMI induced by coronary artery ligation in
rats. Administration of cell culture medium or viable
PBMC served as controls. Immunohistological analysis
was performed to analyse the cellular inﬁltrate in the
ischaemic myocardium. Cardiac function was quantiﬁed by
echocardiography. Planimetry of the infarcted hearts
showed a signiﬁcant reduction of infarction size and an
improvement of post AMI remodelling in rats treated with
suspensions of apoptotic PBMC (injected either intrave-
nously or intramoycardially). Moreover, these hearts evi-
denced enhanced homing of macrophages and cells
staining positive for c-kit, FLK-1, IGF-I and FGF-2 as
compared to controls. A major ﬁnding in this study further
was that the ratio of elastic and collagenous ﬁbres within
the scar tissue was altered in a favourable fashion in rats
injected with apoptotic cells. Intravenous or intramyocar-
dial injection of apoptotic cell suspensions results in
attenuation of myocardial remodelling after experimental
AMI, preserves left ventricular function, increases homing
of regenerative cells and alters the composition of cardiac
scar tissue. The higher expression of elastic ﬁbres provides
passive energy to the cardiac scar tissue and results in
prevention of ventricular remodelling.
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Introduction
Within the last decades early reperfusion therapy signiﬁ-
cantly reduced mortality following acute myocardial
infarction (AMI) and also improved survival and prognosis
of patients. However, the development of chronic
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DOI 10.1007/s00395-011-0173-0ischaemic heart disease and congestive heart failure rep-
resents one of the most frequent causes of hospitalisation in
developed countries, particularly in patients with a large
myocardial infarction [7, 41]. New therapeutic concepts
were developed to reduce the risk of heart failure after an
ischaemic event, ranging from the use of steroids in the 70s
up to cell therapeutic strategies which were assessed in
clinical trials over the last few years [6, 23, 34, 44]. More
recently, new concepts were developed in cardiovascular
research as how to modulate the paracrine and cellular
response after myocardial ischaemia and by doing so
reducing the loss of vital myocardium [15, 35]. It was
shown that tumour necrosis factor alpha (TNF-alpha) acts
as a major player in the post AMI paracrine microenvi-
ronment in a bidirectional way by not only causing tran-
sient contractile dysfunction but also by inducing
cardioprotective effects. Concomitantly, regulating factors
for TNF are up-regulated in stressed cardiac myocytes [8].
Moreover, TNF-alpha signalling also interacts with scar
tissue formation after AMI by targeting ﬁbroblasts, angio-
genesis and also the system of matrixmetalloproteinases
(MMP) and their inhibitors [2, 19, 36, 40]. More recently,
studies further elucidated how paracrine factors mediate
not only the tight regulation of post AMI inﬂammation but
also cardioprotection after ischaemia which subsequently
inﬂuences the formation of scar tissue and ventricular
remodelling after AMI [5, 25].
These observations indicate that a rapid transition to the
reparative phase after AMI mediated by cytokines, mac-
rophages and myoﬁbroblasts is a prerequisite for the
preservation of cardiac function after ischaemia. Never-
theless, the ﬁbrotic scar represents a thin, weakened area
that is unable to withstand the pressure and volume load on
the heart in the same manner as healthy myocardium
would. The intraventricular pressure stresses the infarcted
area with each contraction of the heart, the scar expands
and the left ventricular chamber dilates over time [33].
Recent research has suggested that cardiac function may be
improved after AMI by modifying the composition of
myocardial scar tissue. One way of doing so could be to
alter the ratio of elastic and collagenous ﬁbres within
the scar tissue in a positive way which would support the
contractility of the damaged heart. Elastin is one of the
major insoluble extracellular matrix components and con-
sists of a core of tropoelastin surrounded by ﬁbrillin and
microﬁbrils. The elastin ﬁbre network provides (scar) tis-
sue with a critical property of elasticity and resilient recoil
and maintains the architecture against repeated expansion.
The elasticity of the myocardium highly depends on the
ratio of muscle ﬁbres to ﬁbrotic tissue composed of cross-
linked collagen [22]. A higher ratio of elastin expression in
the myocardial scar may be able to alter the composition of
the ventricular scar tissue in a way to preserve the elasticity
of the infarcted heart. Based on these aspects, Mizuno et al.
[27, 28] have shown that endothelial cells transfected with
a plasmid vector containing the elastin gene increased
elastic ﬁbre expression within the scar signiﬁcantly and
preserved ventricular function in a rat model of AMI.
Another approach to prevent ventricular remodelling
was investigated in an abundance of (pre-)clinical trials of
stem cell therapy after AMI. Recently, this concept came
under critical investigation since most clinical trials
showed only inconsiderable beneﬁcial results compared to
control patients or these effects lasted only for a short
period of time [3, 26]. Based on these results we sought to
investigate an alternative approach namely whether injec-
tion of apoptotic cell suspensions shortly after AMI can
prevent ventricular remodelling by combining immuno-
modulatory and pro-angiogenic effects. In 2005, this
therapeutic principle was ﬁrst described in a hypothesis by
Thum et al. [38]. Several reports have substantiated this
perception by showing the protective potential of stressed
or apoptotic cell suspensions in various ischaemic disease
entities [1, 11]. Moreover, experimental pre-treatment of
spontaneously hypertensive rats with apoptotic cells
reduced severe renal ischaemia reperfusion injury [39]. In
a model of acute inﬂammatory lung injury, the adminis-
tration of apoptotic cells enhanced the resolution of
inﬂammation via increased TGF-beta secretion [17]. Of
mechanistic relevance are also reports that demonstrate
that infusion of apoptotic cells lead to allogeneic hema-
topoietic cell engraftment in a transplantation model and to
a delay of lethal acute graft-versus-host disease (GVHD)
[4, 31]. Moreover, infusion of donor apoptotic cells
increased heart graft survival in a solid organ transplan-
tation model [37].
However, the exact mechanism by which apoptotic
cells can alter immune reactions after AMI and interfere
with post-AMI tissue remodelling still remains to be elu-
cidated. In our previous research, we have provided evi-
dence that irradiation and induction of apoptosis in human
peripheral blood mononuclear cells (PBMC) increased
mRNA transcripts of Interleukin-8 and MMP9, two
important factors for progenitor cell liberation from the
bone marrow and their homing to sites of ischaemia [1].
Therefore, we sought to further elucidate the pleiotropic
effects which apoptotic cells can induce when injected as a
suspension in an experimental model of AMI. Here we
show that suspensions of irradiated apoptotic PBMC
injected either intravenously or intramyocardially cause
progenitor cell homing to sites of myocardial ischaemia,
prevent ventricular remodelling and alter the composition
of cardiac scar tissue after AMI. This new concept evi-
dences many convenient characteristics which are parti-
cularly of relevance compared to the therapeutic strategies
mentioned earlier.
646 Basic Res Cardiol (2011) 106:645–655
123Methods
Acquisition of syngeneic rat PBMC suspensions
for in vivo experiments
Animal experiments were approved by the committee for
animal research, Medical University of Vienna (vote:
BMBWK-66.009/0278-BrGT/2005). All experiments were
performed in accordance to the Guide for the Care and Use
of Laboratory Animals by the National Institutes of Health
(NIH Publication No. 85-23, revised 1996). Syngeneic rat
PBMC for in vivo experiments were separated by density
gradient centrifugation from whole blood obtained from
prior heparinized rats by direct punctuation of the heart.
Cells were separated by Ficoll-Paque (GE Healthcare Bio-
Sciences AB, Sweden) density gradient centrifugation.
Apoptosis of PBMC was induced by Caesium-137 irradi-
ation (Department of Transfusion Medicine, General Hos-
pital Vienna) with 45 Gray (Gy). Cells were resuspended
in serum-free UltraCulture Medium (UltraCulture, Lonza,
Switzerland) and cultured in a humidiﬁed atmosphere for
18 h. Induction of apoptosis was measured by Annexin-V/
propidium iodine (FITC/PI) co-staining (Becton–Dickin-
son, Franklin Lakes, NJ, USA) on a ﬂow cytometer.
Annexin-positivity of PBMC was determined as[80% and
these cells were consequently termed apoptotic PBMC
(irradiated apoptotic PBMC, IA-PBMC).
Experimental rat model of acute myocardial infarction
Acute myocardial infarction was induced in adult male
Sprague–Dawley rats (weight 300–350 g) by ligating the
left anterior descending artery (LAD) as described previ-
ously [1]. In short, animals were anaesthetized intraperi-
toneally with a mixture of xylazine (1 mg/100 g
bodyweight) and ketamine (10 mg/100 g bodyweight) and
ventilated mechanically. A left lateral thoracotomy was
performed and a ligature using 6-0 prolene was placed
around the LAD beneath the left atrium. Immediately after
the onset of ischaemia, cell suspensions of 8.5 9 10
6 cells
viable or apoptotic PBMC suspended in 0.3 mL Ultra-
Culture Medium were injected in the femoral vein. Fur-
thermore, apoptotic cells (8.5 9 10
6 cells) were also
injected directly into the myocardium at ﬁve different sites
of the peri-infarct zone. Injection of cell culture medium
alone and sham operation served as controls in this
experimental setting.
Histology and immunohistochemistry
Animals were killed either 72 h or 6 weeks after experi-
mental infarction. Hearts were explanted and then sliced at
three layers at the level of the largest extension of infarcted
area (n = 6 for 72 h analyses, n = 10–12 for 6 weeks
analyses). Slices were ﬁxed in 10% neutral buffered for-
malin and embedded in parafﬁn. The tissue samples were
stained with hematoxylin–eosin (H&E) and Elastica van
Gieson (EVG). Immunohistochemical evaluation 72 h after
AMI was performed using the following antibodies direc-
ted to CD68 (MCA 341R, AbD Serotec, Kidlington, UK),
c-kit (sc-168, Santa Cruz Biotechnology, CA, USA), FLK1
(sc-6251, Santa Cruz Biotechnology, CA, USA), IGF-I (sc-
9013, Santa Cruz Biotechnology, CA, USA) and FGF-2
(sc-79, Santa Cruz Biotechnology, CA, USA). Tissue
samples were evaluated on an Olympus AX70 microscope
(Olympus Optical Co. Ltd., Tokyo, Japan) at 2009 mag-
niﬁcation and captured digitally using Meta Morph v4.5
Software (Molecular Devices, Sunnyvale, USA). Image J
planimetry software (Rasband, W.S., Image J, U.S.
National Institutes of Health, Bethesda, USA) was utilised
to determine the area of necrosis after 3 days and the size
of myocardial infarct after 6 weeks. The extent of infarcted
myocardial tissue (% of left ventricle) was calculated by
dividing the area of the circumference of the infarcted area
by the total endocardial and epicardial circumferenced
areas of the left ventricle. Planimetric evaluation after
6 weeks was carried out on tissue samples stained with
EVG for better comparison of vital myocardium and
ﬁbrotic areas. Infarction size was expressed as a percentage
of the total left ventricular area. EVG stained tissue spec-
imens were analysed microscopically for the ratio of elastic
and collagen ﬁbres. Using Image J Planimetry software, the
ratio was calculated by dividing the area occupied by
elastic ﬁbres by the total area of scar tissue.
Assessment of cardiac function by echocardiography
Six weeks after induction of myocardial infarction, rats
were anaesthetized with 100 mg/kg ketamine and 20 mg/
kg xylazine. The sonographic examination was conducted
on a Vivid 7 system (General Electric Medical Systems,
Waukesha, USA). Analyses were performed by an expe-
rienced observer blinded to the treatment groups to which
the animals were allocated. M-mode tracings were recor-
ded from a parasternal short-axis view and functional
systolic and diastolic parameters were obtained (shortening
fraction, SF; left ventricular end-diastolic diameter,
LVEDD; left ventricular end-systolic diameter, LVESD).
Shortening fractional was calculated as follows: SF(%) =
((LVEDD - LVESD)/LVEDD) 9 100.
Cell culture of human PBMC
Human peripheral blood mononuclear cells (PBMC) were
obtained from young healthy volunteers after informed
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123consent. All experimental procedures were approved by the
Regional Committee for Medical Research Ethics (ethics
committee vote: EK-Nr 2010/034) and were conducted in
compliance with the Declaration of Helsinki Principles.
Cells were separated by Ficoll-Paque (GE Healthcare Bio-
Sciences AB, Sweden) density gradient centrifugation.
Apoptosis of PBMC was induced by Caesium-137 irradi-
ation with 60 Gray (Gy) for in vitro experiments. Cells
were resuspended in serum-free UltraCulture Medium and
cultured in a humidiﬁed atmosphere for 24 h at a density of
2.5 9 10
6 cells/mL, n = 5. Induction of apoptosis was
measured by Annexin-V/propidium iodine (FITC/PI) co-
staining (Becton–Dickinson, Franklin Lakes, NJ, USA) on
a ﬂow cytometer. Annexin-positivity of PBMC was
determined to be[80% in order to characterise apoptotic
cells.
Fibroblast cell culture, RNA isolation and cDNA
preparation
Cell Culture supernatants were obtained from viable
PBMC, IA-PBMC and mixed co-cultures of viable cells
and IA-PBMC after 24 h (cell density 2.5 9 10
6 suspended
in UltraCulture Medium). 1 9 10
5 human primary ﬁbro-
blasts (Cascade Inc., Portland, USA) were exposed to
supernatants obtained from viable PBMC, apoptotic PBMC
and mixed cultures of viable and apoptotic cells for 24 h.
Fibroblasts were grown in Dulbecco’s modiﬁed Eagle
medium (DMEM, Gibco BRL, Gaithersburg, USA) sup-
plemented with 10% foetal bovine serum (FBS, PAA, Linz,
Austria), 25 mM L-glutamine (Gibco BRL, Gaithersburg,
USA) and 1% penicillin/streptomycin (Gibco) and seeded
in 12 well plates. After RNA extraction of ﬁbroblasts
(using RNeasy, QiIAGEN, Vienna, Austria) following the
manufacturer’s instruction, cDNAs were transcribed using
the iScript cDNA synthesis kit (BioRad, Hercules, USA) as
indicated in the instruction manual.
Quantitative real time polymerase chain reaction
(RT-PCR)
mRNA expression was quantiﬁed by real time PCR with
LightCycler Fast Start DNA Master SYBR Green I (Roche
Applied Science, Penzberg, Germany) according to the
manufacturer’s protocol. The primers for Elastin (forward:
50-CCTACTTACGGGGTTGG-30, reverse: 50-GCCGAGC
AGACAAGAA-30), Collagen Type I (forward: 50-GTGCT
AAAGGTGCCAATGGT-30, reverse: 50-CTCCTCGCTTT
CCTTCCTCT-30), Collagen Type III (forward: 50-GTCC
ATGGATGGTGGTTTTC-30, reverse: 50-CACCTTCAT
TTGACCCCATC-30), Collagen Type V (forward: 50-GT
CCATACCCGCTGGAAA-30, reverse: 50-TCCATCAGG
CAAGTTGTGAA-30), IL-8 (forward: 50-CTCTTGGCAG
CCTTCCTGATT-30, reverse: 50-TATGCACTGACATCT
AAGTTCTTTAGCA-30), MMP1 (forward: 50-GGTCTCT
GAGGGTCAAGCAG-30, reverse: 50-CCGCAACACGAT
GTAAGTTG-30), MMP3 (forward: 50-TGCTTTGTCCT
TTGATGCTG-30, reverse: 50-GGCCCAGAATTGATTTC
CTT-30), MMP9 (forward: 50-GGGAAGATGCTGGTGT
TCA-30, reverse: 50-CCTGGCAGAAATAGGCTTC-30)
and b-2-microglobulin (b2M, forward: 50-GATGAGTAT
GCCTGCCGTGTG-30, reverse: 50-CAATCCAAATGCGG
CATCT-30) were designed as described previously [18].
The relative expression of the target genes was calculated
by comparison with the house keeping gene b2M using a
formula described by Pfafﬂ et al. [32]. The efﬁciencies of
the primer pairs were determined as described [18].
Evaluation of cytokines and growth factors secreted
by apoptotic PBMC
Membrane arrays for the detection of cytokines and growth
factors in pooled cell culture supernatants derived from
non-irradiated and IA-PBMC (cultured at a density of
2.5 9 10
6/ml, cells obtained from 4 healthy volunteers)
were performed to scan the protein content (AAH-CYT-
G4000, RayBiotech, Norcross, USA). Experiments were
performed according to the manufacturer’s protocol.
Statistical methods
Statistical analysis was performed using GraphPad Prism
software (GraphPad Software, La Jolla, USA). All data are
given as mean ± standard error of the mean (SEM). The
Wilcoxon-Mann–Whitney-Test was utilised to calculate
signiﬁcances between the groups. p values \0.05 were
considered statistically signiﬁcant (p values were expressed
as follows: *p\0.05, **p\0.01, ***p\0.001).
Results
Histological and immunohistological analysis
of explanted hearts 3 days after AMI
Since the inﬂammatory response after acute ischaemia
determines the road map to ventricular dilation, we per-
formed histological analysis after 72 h after AMI in order
to study short term effects of intravenous (IV) or intra-
myocardial (IM) injection of apoptotic cell suspensions.
H&E stained specimens obtained from control AMI ani-
mals evidenced a mixed cellular inﬁltrate in the wound
areas in accordance with granulation tissue with abundance
of neutrophils, macrophages/monocytes, lymphomono-
nuclear cells admixed to dystrophic cardiomyocytes within
648 Basic Res Cardiol (2011) 106:645–655
123the ﬁrst 72 h after AMI (Fig. 1a,b). In contrast, rats treated
with apoptotic PBMC suspensions evidenced a dense
monomorphic inﬁltrate in wound areas (Fig. 1c,d). Fur-
thermore, the total area of necrosis was signiﬁcantly
smaller in rats injected with apoptotic cells in comparison
to controls (Fig. 1e). Immunohistological analysis revealed
that the cellular inﬁltrate in both treatment groups (intra-
venous and intramyocardial injection) was composed of
abundant CD68? monocytes/macrophages that was much
weaker in the control group (Fig. 1f–j). Cell counts quan-
tiﬁed per high power-ﬁeld (HPF) were 28.6 ± 2.4 (±SEM)
in control, 36.0 ± 3.5 (±SEM) in animals injected with
non-irradiated viable cells compared to 55.3 ± 3.4 and
76.5 ± 5.9 (± SEM) in rats treated with apoptotic cells (IV
or IM, respectively). In addition, most of the medium-sized
monocytoid cells were identiﬁed to be highly positive for
c-kit (CD117) and vascular endothelial growth factor
receptor 2 (FLK-1). High power-ﬁeld (HPF) cell counts for
c-kit were 68.0 ± 3.1(±SEM) in controls, 77.0 ± 4.6
(±SEM) in the group injected with viable cell versus
121.2 ± 9.4 (±SEM) in IV and 168.6 ± 12.4 (±SEM) in
IM injected rats (Fig. 1k–o). For FLK-1, values were
58.3 ± 5.6 (±SEM) in controls, 86.0 ± 7.0 (±SEM) for
viable cell injected rats, 170.3 ± 7.1 (±SEM) for IV and
202.0 ± 9.4 (±SEM) for IM injected rats (Fig. 1p–t).
Expression of these three cellular markers was more
accentuated in rats injected with apoptotic cell suspensions
compared to the control AMI group. (see representative
images Fig. 1, n = 5–6 per group).
Histological analysis 6 weeks after induction of AMI
Cardiac tissue specimens obtained 6 weeks after ligation
of the LAD and stained according to the Elastica van
Gieson protocol showed that hearts from rats injected
with apoptotic PBMC suspensions showed a highly sig-
niﬁcant reduction of infarction area. Figure 3a shows
representative images which evidence that rats treated
with apoptotic cells demonstrate a signiﬁcantly greater
extent of viable myocardium within the anterior free wall
of the left ventricle. In contrast, collagen deposition and
scar formation extended through almost the entire left
ventricular wall thickness in rats receiving control med-
ium. Compared to controls and viable injected animals the
left ventricular geometry was almost completely pre-
served in rats treated with irradiated apoptotic cell sus-
pensions. The area of ﬁbrosis as calculated by planimetry
was 25% (percent of the left ventricle) in medium
injected controls, 14% in viable cell injected animals
compared to 6% (IV) and 8% (IM) in rats treated with
apoptotic PBMC suspensions (p\0.01 vs. controls,
p\0.05 vs. viable cell injected animals, n = 10–12 per
group) (Fig. 2a,b).
Evaluation of functional parameters
by echocardiography
Cardiac function was evaluated by means of echocardiog-
raphy. Six weeks after ligation of the LAD the mean left
ventricular shortening fractions (SF), left ventricular end-
diastolic diameters (LVEDD), left ventricular end-systolic
diameters (LVESD) were determined to be 19% ± 1 (SF),
10.4 mm ± 0.2 (LVEDD), 8.5 mm ± 0.2 (LVESD) in
animals that received culture medium alone (±SEM). In
animals injected with viable cells similar values were
obtained: 18% ± 2 (SF), 11.0 mm ± 0.4 (LVEDD),
9.0 mm ± 0.5 (LVESD),
Noteworthy, rats with intravenous injection of apoptotic
cell suspensions evidenced signiﬁcantly improved func-
tional parameters: 25% ± 3 (SF), 8.9 mm ± 0.3
(LVEDD), 6.8 mm ± 0.4 (LVESD). In animals with direct
intramyocardial injection of apoptotic cells these parame-
ters were improved as well: 26% ± 2 (SF), 9.8 mm ± 0.4
(LVEDD), 7.4 mm ± 0.5 (LVESD). Mean levels of car-
diac function of healthy rats without myocardial infarction
(sham operated) were as follows: 29% ± 2 (SF),
9.2 mm ± 0.4 (LVEDD), 6.5 mm ± 0.3 (LVESD), (p\
0.05 vs. viable cell injected animals and medium injected
controls, n = 10–12 per group) (Fig. 2c–e).
These ﬁndings indicate a signiﬁcant improvement or
preservation of cardiac function in both treatment groups
that were injected with apoptotic cell suspensions. Rats that
were injected with viable non-irradiated PBMC or fresh
culture medium showed signs of dilation which were
accompanied by a considerable loss of ventricular function.
Alterations in the composition of the ﬁbrotic scar tissue
Six weeks after AMI the composition of the ﬁbrotic scar
tissue was analysed microscopically (Elastica van Gieson
staining). Especially within the border zone between viable
myocardium and scar tissue a highly remarkably accumu-
lation of elastic ﬁbres was detected in animals injected with
suspensions of apoptotic cells compared to controls
(Fig. 3a–d). A planimetric analysis revealed that the
ﬁbrotic scar in apoptotic cell (IV and IM) injected rats was
composed by 5.5% ± 1.1 and 8.9% ± 2.2 of elastic ﬁbres
compared to 0.2% ± 0.1 in controls and 2.9% ± 0.2 in
viable injected animals (Fig. 3e), (p\0.001 vs. control,
n = 10–12 per group). This ﬁnding stands in relation to
higher levels of cells stained positive for insulin-like
growth factor I (IGF-I) and ﬁbroblast growth factor 2
(FGF-2) in treated animals (Fig. 3i–k) compared to con-
trols (Fig. 3f–h). In animals that were injected with apop-
totic cell suspensions 36.0 ± 3.3 cells staining positive for
IGF-I and 49.8 ± 5.2 for FGF-2 were found in immuno-
histological analyses of myocardial specimens 72 h after
Basic Res Cardiol (2011) 106:645–655 649
123LAD ligation. In controls only 7.0 ± 1.6 IGF-I and
31.5 ± 2.3 FGF-2 positive cells were detectable.
In order to specify the association of elastin and colla-
gen production within myocardial scar tissue and mecha-
nisms induced by apoptotic cells RT-PCR analyses were
conducted. When exposing ﬁbroblasts to cell culture
supernatants obtained from apoptotic PBMC or apoptotic
cells co-incubated with viable cells elastin expression
increased only slightly by 1.2- to 1.4-fold. The expression
of collagen type III and IV increased moderately by 1.9- to
2.5-fold compared to controls (Fig. 3l). Supernatants
derived from apoptotic cells also increased the expression
of IL-8 (4- to 6.5-fold), MMP1 (18- to 31-fold), MMP3
(10- to 16-fold) and MMP9 (4- to 7-fold) in ﬁbroblasts
indicating a mechanistic cross-talk between apoptotic cells,
their secretome and resident cells that could be accounted
for alterations of the compositions of the extracellular
matrix (Fig. 3m).
Analysis of paracrine factors secreted by non-irradiated
and irradiated apoptotic cells
Based on the ﬁnding that the expression of transcripts for
IL-8 and MMPs were up-regulated in apoptotic cells we
screened the supernatant obtained from irradiated and non-
irradiated cell for 274 cytokines and growth factors. Con-
siderable differences were observed (amongst others) for
IL-8, VEGF, MMP3, MMP9, IL-16, ENA-78 and MIP-
1alpha (see supplementary table).
Discussion
Over the last decade, cardiovascular research has focused
on determining clinical protocols for stem cell therapy in
order to salvage damaged myocardium after AMI. Here we
present evidence that suspensions of apoptotic cells can
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Fig. 1 Results 3 days after AMI induction: H&E stained rat myo-
cardium 3 days after LAD ligation. The cellular inﬁltrate appears to
be more consolidated in apoptotic PBMC treated animals (a–d). The
total area of necrosis was signiﬁcantly reduced in both treatment
groups compared to controls (e). Below, myocardial tissue stained for
CD68 is shown (f–i). Quantiﬁcation of positively stained cells per
high power-ﬁeld (HPF) indicated higher numbers of macrophages in
both treatment groups (h–j). When tissue specimens were stained for
c-kit (k–n), more of these cell populations could be detected in the
epicardial zone in rats injected with apoptotic cells (m–o). Concom-
itantly, more cells staining positive for FLK-1/VEGF receptor 2 were
found in the same areas (p–t)
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123serve as a potent therapeutic entity for preserving ventric-
ular function after ischaemia when being injected shortly
after occlusion of a coronary artery. We could show that
apoptotic PBMC act in a cardioprotective manner by
pleiotropic effects, ﬁrst of all, the expression of the pro-
angiogenic chemokine IL-8 and various matrixmetallo-
proteinases is induced in cells when being exposed to the
conditioned medium of apoptotic PBMC. IL-8 and MMP9
are factors which are of great importance for reparative
processes in the ischaemic heart by enabling progenitor cell
populations of the bone marrow to enter the circulation and
home to sites of myocardial damage [14, 20]. Conse-
quently, more cells staining positive for c-kit and FLK-1/
VEGF receptor 2 were detected in the myocardium of rats
injected with apoptotic cells. This phenomenon was
detectable even to a much greater extent when irradiated
cells where injected directly into the ischaemic tissue.
Furthermore, also higher numbers of macrophages where
found in the ischaemic myocardium 3 days after induction
of AMI, suggesting an accelerated repair phase in both
treatment groups. When interpreting our data obtained by
immunohistology correctly, we believe that injection of
apoptotic cell suspensions shortly after AMI results in
quicker changeover from an inﬂammatory phase to tissue
inﬁltration of c-kit?/FLK-1 cells into the ischaemic myo-
cardium causing increased angiogenesis in the early phase
after AMI [30]. Previous work has conﬁrmed that bone
marrow progenitor cells improve cardiac function after
AMI, regardless of whether transdifferentiation of the cells
to cardiomyocytes occurs or not [29]. Fazel et al. deﬁned
the signiﬁcant role of bone marrow derived c-kit? cells as
an essential population for cardiac repair. In a knock-out
model of c-kit it has been shown that the triggering of this
receptor is a necessary prerequisite for bone marrow pro-
genitor cell mobilization after ischaemia since c-kit dys-
function led to a reduced myoﬁbroblast repair response and
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123subsequently to cardiac failure after experimental AMI. It
was also determined that c-kit activation requires the
activity of MMP9 within the bone marrow compartment [9,
12, 13]. Regarding our own data this correlates with an up-
regulation of MMP transcripts in ﬁbroblasts when exposed
to conditioned medium obtained from cell cultures of
apoptotic cells.
Six weeks after ligation of the LAD, a further important
ﬁnding was that the treatment with apoptotic cells also
attenuated the extent of infarction in this experimental AMI
model. This also became apparent in echocardiography.
Animals injected with irradiated apoptotic cell suspensions
evidenced a signiﬁcant improvement of all tested func-
tional parameters.
Also of great interest was the ﬁnding that the compo-
sition of the extracellular matrix within the scar tissue was
evidently altered compared to the controls. In Elastica van
Gieson stained specimens, a considerable accumulation of
elastic ﬁbres, especially, in the border zone between vital
cardiomyocytes and the ﬁbrotic scar was detected. This
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cantly more elastic ﬁbres were found within the scar tissue of AMI
rats injected with apoptotic PBMC. f, g Specimens stained for IGF-I
in controls and treated animals. i, j Immunohistological staining for
FGF-2. More cells staining positive for IGF-I and FGF-2 were found
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123alteration in the elastin/collagen ratio could be a major
factor contributing to the improvement of cardiac function
parameters in rats injected with apoptotic cells. This was
even more pronounced when these cell suspensions were
injected directly into the ischaemic myocardium. Together
with the increased accumulation of elastic ﬁbres we also
found higher numbers of cells staining positive for insulin-
like growth factor I (IGF-I) and ﬁbroblast growth factor 2
(FGF-2). It has been reported that these two growth factors
contribute directly to the synthesis of elastic ﬁbres within
the extracellular matrix and regulate cardiac repair mech-
anisms after AMI [10, 21, 24, 42, 43]. There are a number
of possible mechanisms by which a favourable ratio of
elastic and collagenous ﬁbres in the myocardial scar tissue
could delay the onset of ventricular dysfunction and
remodelling. A cardiac scar tissue showing more elastic
properties and being more resistant could function as a
shock absorbing cushion thus reducing the tractive effects
of the acute increase in intraventricular pressure on the scar
during systole. The recoil of the elastic fragments in the
scar could provide passive energy to return the scar size
and ventricular chamber volume to precontractile dimen-
sions. These mechanistic characteristics are important for
preventing or reducing the risk for ventricular remodelling.
Conclusion
In summary, we believe that PBMC undergoing apoptotic
cell death feature many pleiotropic effects which evidence
multiple beneﬁcial characteristics in the setting of (experi-
mental) AMI. Based on these data we conclude that
apoptotic cells induce the expression of pro-angiogenic
factors necessary for attraction of regenerative cells to sites
of ischaemia. An additional mechanistic concept has
already been discussed in the scientiﬁc literature and states
that apoptotic cells interact with surrounding cells causing
immunomodulation [16]. A modulatory effect on invading
inﬂammatory cells into the ischaemic myocardium could
also prove to be beneﬁcial by reducing the secondary
damage caused by neutrophils in the early stages after
AMI. The combination of these mechanisms leads to a
quicker resolution of the inﬂammatory phase after AMI,
induces the homing of CD68?, c-kit? and FLK-1? cells,
accelerates reparative processes, alters the elastin/collagen
ratio within the scar tissue in a beneﬁcial way and in the
end improves ventricular function.
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